Privacy Notice, and The company was founded in 2013 by Katherine A. Read full article. Vi og vores partnere opbevarer og/eller har adgang til oplysninger om din enhed via brugen af cookies og lignende teknologier for at vise personligt tilpassede annoncer og personligt tilpasset indhold, til måling af annoncer og indholds effektivitet, til indsigt om målgrupper samt produktudvikling. Check out the latest earnings call transcript for Spark. December 3, 2019, 2:46 PM. By using this site you agree to the Is Spark Therapeutics Inc (ONCE) A Good Stock To Buy? Du kan ændre dine valg når som helst i Dine kontrolfunktioner til beskyttelse af private oplysninger. Dine kontrolfunktioner til beskyttelse af private oplysninger, Oplysninger om din enhed og internetforbindelse, herunder din IP-adresse, Browsing- og søgeaktivitet ved brug af websites og apps fra Verizon Media. Subscriber Agreement & Terms of Use, Demitri covers consumer goods and media companies for Fool.com, as well as broader moves in the economy. Feb 25, 2019 11:37 AM EST . MARKETS. De Telmont, J.D. Last month's rally came as a result of the biotech company announcing an agreement to be purchased by Roche Holdings (OTC:RHHBY) for nearly $5 billion, or $114.50 per share. Historical and current end-of-day data provided by FACTSET. Nina Todic. Spark Therapeutics shareholders should see their stock holdings convert to cash at that $114.50 price when the deal closes sometime in the second quarter of 2019. Spark Therapeutics, Inc. is a developer of gene therapy treatments, which treat debilitating genetic diseases. Yahoo er en del af Verizon Media. Get instant access to a free live streaming chart of the Spark Therapeutics Inc Stock. Autos and apparel makers boost European stocks, while U.S. equity futures struggle, EU new car sales rise for the first time this year, Remy Cointreau buys Champagne House J. Returns as of 10/16/2020.

Cumulative Growth of a $10,000 Investment in Stock Advisor, Why Spark Therapeutics Stock Soared 137% in February @themotleyfool #stocks $ONCE $RHHBY, Why Coeur Mining, Spark Therapeutics, and Tandem Diabetes Care Slumped Today, Why Spark Therapeutics Is Skyrocketing 120% Today, Spark Therapeutics (ONCE) Q4 2018 Earnings Conference Call Transcript, 2 Sets of Disasters Biotech Will Pay For in 2019, Copyright, Trademark and Patent Information. After that, the company will continue to operate as an independent group within Roche Holdings, but will benefit from its parent's global reach as it seeks to better commercialize treatments like its Luxturna genetic eye disease drug. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. It is a subsidiary of Hoffmann-La Roche History. Stock Advisor launched in February of 2002. ONCE | Complete Spark Therapeutics Inc. stock news by MarketWatch. Få mere at vide om, hvordan vi bruger dine oplysninger i vores Fortrolighedspolitik og Cookiepolitik. See you at the top! Spark Therapeutics (NASDAQ:ONCE) stock outpaced the market by a wide margin last month, gaining 137% compared to a 3% spike in the S&P 500, according to data provided by S&P Global Market Intelligence. Intraday data delayed at least 15 minutes or per exchange requirements. Spark Therapeutics (NASDAQ:ONCE) stock outpaced the market by a wide margin last month, gaining 137% compared to a 3% spike in the S&P 500, according to … That deal ensures positive returns for all shareholders, which counts as a solid win in the volatile biotech world. Spark Therapeutics Rockets as Roche Pays $4.3 Billion for Gene Therapy Experts. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life.

Du kan give Verizon Media og vores partnere lov til at behandle dine personlige data ved at vælge 'Jeg accepterer'. All quotes are in local exchange time. The increase put shareholders back in significantly positive territory, with returns of over 70% in the past year versus a 3% increase in the broader market. Cookie Notice. That price equates to a 122% premium over the stock's value on trading day prior to the deal's announcement. This browser is no longer supported at MarketWatch. Du kan også vælge 'Administrer indstillinger', hvis du vil have mere at vide og for at administrere dine valg. Why Spark Therapeutics Stock Soared 137% in February Why Spark Therapeutics Is Skyrocketing 120% Today Spark Therapeutics (ONCE) Q4 2018 Earnings Conference Call Transcript Market data powered by FactSet and Web Financial Group. By Martin Baccardax. Why Spark Therapeutics Stock Soared 137% in February Why Spark Therapeutics Is Skyrocketing 120% Today Spark Therapeutics (ONCE) Q4 2018 Earnings Conference Call Transcript Copyright © 2020 MarketWatch, Inc. All rights reserved. Let's conquer your financial goals together...faster. Wetherspoon swings to loss amid lockdowns, Warm Words for Covid-19 Treatments Need to Turn Into Action, Daimler delivers upbeat outlook after strong 3Q. View real-time stock prices and stock quotes for a full financial overview. View the latest Spark Therapeutics Inc. (ONCE) stock price, news, historical charts, analyst ratings and financial information from WSJ. Intraday Data provided by FACTSET and subject to terms of use. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. For the best MarketWatch.com experience, please update to a modern browser.